4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Sell
20
PHIO Quote, Financials, Valuation and Earnings
Last price:
$1.69
Seasonality move
:
-4.4%
Day range:
$1.61 - $1.70
52-week range:
$1.53 - $10.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.36x
Volume:
48.7K
Avg. volume:
673.2K
1-year change:
-74.15%
Market cap:
$1.8M
Revenue:
--
EPS (TTM):
-$10.91
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Phio Pharmaceuticals has 2030.18% upside to fair value with a price target of -- per share.
PHIO vs. S&P 500
-
Over the past 5 trading days, Phio Pharmaceuticals has underperformed the S&P 500 by -9.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Phio Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Phio Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Phio Pharmaceuticals reported revenues of --.
Earnings Growth
-
Phio Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Phio Pharmaceuticals reported earnings per share of -$1.54.
Enterprise value:
-3.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.2M | -$11.7M | -$7.5M | -$2.8M | -$1.6M | |
| EBITDA | -$11.9M | -$11.5M | -$7.4M | -$2.7M | -$1.6M | |
| Diluted EPS | -$96.89 | -$73.47 | -$10.91 | -$10.25 | -$1.54 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.6M | $27.5M | $15.4M | $9.3M | $5.9M | |
| Total Assets | $18.2M | $27.9M | $15.8M | $9.5M | $5.9M | |
| Current Liabilities | $2.2M | $2.5M | $2.2M | $2.3M | $919K | |
| Total Liabilities | $2.8M | $2.7M | $2.3M | $2.3M | $919K | |
| Total Equity | $15.5M | $25.2M | $13.5M | $7.2M | $4.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.9M | -$11.1M | -$8.1M | -$2.9M | -$2M | |
| Cash From Investing | -$121K | -- | -- | -- | -- | |
| Cash From Financing | -$29K | $5M | $5M | -- | $2.6M | |
| Free Cash Flow | -$12M | -$11.1M | -$8.1M | -$2.9M | -$2M | |
PHIO
Sector
Market Cap
$1.8M
$47.5M
Price % of 52-Week High
16.33%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-74.15%
-34.04%
Beta (5-Year)
1.511
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.83
200-day SMA
Sell
Level
$4.25
Bollinger Bands (100)
Sell
Level
2.31 - 3.27
Chaikin Money Flow
Sell
Level
-143.9M
20-day SMA
Sell
Level
$2.15
Relative Strength Index (RSI14)
Sell
Level
34.76
ADX Line
Sell
Level
8.73
Williams %R
Buy
Level
-89.1156
50-day SMA
Sell
Level
$2.52
MACD (12, 26)
Sell
Level
-0.24
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
390.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Stock Forecast FAQ
In the current month, PHIO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHIO average analyst price target in the past 3 months is --.
-
Where Will Phio Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Phio Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Phio Pharmaceuticals?
Analysts are divided on their view about Phio Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Phio Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Phio Pharmaceuticals's Price Target?
The price target for Phio Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Phio Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PHIO?
You can purchase shares of Phio Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Phio Pharmaceuticals shares.
-
What Is The Phio Pharmaceuticals Share Price Today?
Phio Pharmaceuticals was last trading at $1.69 per share. This represents the most recent stock quote for Phio Pharmaceuticals. Yesterday, Phio Pharmaceuticals closed at $1.69 per share.
-
How To Buy Phio Pharmaceuticals Stock Online?
In order to purchase Phio Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
